An unpublished HSE proposal indicates that there is currently little benefit in prescribing Paxlovid, a drug previously celebrated as a 'lifesaver' during the Covid-19 pandemic.
Paxlovid was mainly targeted at at-risk individuals infected with Covid-19, with the intention of reducing hospitalizations and serious illness, but its usage is now questioned.
Collection
[
|
...
]